Intelligence

#Biosensors #Drug discovery #Interaction analysis #Molecular research #Pharmokinetics

Binding kinetics in hours instead of days with label-free interaction analysis

Label-free interaction analysis takes discovery to a new level. It removes inaccuracies and inefficiencies, but it also uncovers a new layer of insight into the kinetic activity and binding specificity of a greater range of analytes. GCI technology brings you closer to your analytes, allowing you to see interactions in… Read More

#Resources

#BioInnovation Institute #Drug discovery #Funding #Investment #Start-ups

Three therapeutics start-ups join acceleration programme

The BioInnovation Institute (BII) has welcomed three new drug discovery start-ups into its Venture Lab acceleration programme as part of its latest cohort of eight companies. The 12-month Venture Lab programme is designed to support start-up companies with business acceleration, scientific and team development, and provides… Read More

#News #Start-up Zone

#Clinical trials #Drug toxicity #Mouse models #Pharmacology #Preclinical investigations

Discover evidence-based, first-in-human dose selection

This whitepaper discusses evidence-based selection of starting doses in first-in-human clinical trials through the utilisation of humanised mouse models and emphasises the importance of accurate dose prediction to ensure patient safety and trial success. In this whitepaper you will learn about: The significance of selecting appropriate starting doses in clinical… Read More

#Resources

Peptide
#Cancer research #HBC Immunology #Oncology #Peptides #Prostate cancer #Seed funding #Tumour microenvironment (TME)

Start-up to study peptides that modulate gene expression

HBC Immunology (a subsidiary of Hofseth BioCare) has secured seed capital financing of approximately $900,000 from external investors to commence preclinical animal trials with its patented peptides, FT-002 and FT-005. These are analogues of peptides discovered by HBC in ProGo bioactive peptides, which modulate iron metabolism… Read More

#News #Start-up Zone

#Biologics #CAR-T #Cell and gene therapy #Cell therapy #PCR

Explore the power of digital PCR for lentiviral vector characterisation

Recombinant lentiviral vectors are used for ex vivo transgene delivery in several gene-modified cell therapies, such as chimeric antigen receptor (CAR) T cell therapy. Reliable analytical methods such as digital PCR to characterise lentiviral vectors and the cells transduced with them are critical to helping ensure the safety and efficacy of… Read More

#Resources

EU and US flags
#Advanced Therapies #Cell and gene therapy #EMA #FDA #Regulatory

Overcoming diverging regulatory expectations to bring CGTs to market

Lung-I Cheng, Vice President and Head of Cell & Gene Therapy Service Line at AmerisourceBergen, and Cori Gorman, Senior Director of CMC and Regulatory Affairs at Biopharma Excellence, offer advice on navigating the different and sometimes contradictory regulatory requirements in the US and EU. Over the… Read More

#Exclusive Content #Regulatory #Trends & Analysis

Science, Safety, Research, Technology and Cannabis
#Cannabinoid #Medicinal cannabis #Plant-based #Regulatory

Where is the promise for plant-based medicines? Part 1: Cannabis  

In the first part of this series of articles focused on plant-based medicines, DDW’s Megan Thomas evaluates the use of medical cannabis in drug discovery. What is the regulatory landscape of medical cannabis?  Medical cannabis is often a first-thought when regarding plant-based medicines, but there remains… Read More

#Exclusive Content #Regulatory #Trends & Analysis

#Biologics #Drug development #Drug discovery #Guide #Monoclonal antibodies #Screening

The biologics researcher’s mini-guide to screening candidates with nanoDSF

Among the most common critical quality attributes (CQAs) for early developability assessment is thermal stability. One particular tool for assessing thermal stability with high resolution is nano-differential scanning fluorimetry (nanoDSF). Read this mini-guide to learn: How nanoDSF uses your protein’s intrinsic fluorescence to determine its melting temperature, Tm and onset… Read More

#Intelligence #Resources

The microbiome
#Drug discovery #Gut microbiome #Microbiome #Precision medicine

The microbiome in precision medicine

Listen to this article on the DDW Podcast: An industry overview of the role of the microbiome in precision medicine, and its interplay with research tools, diagnostics, and therapeutic development. By Katie Gillette, Senior Project Leader, Eliza French, Analyst, and Graham Friedman, Analyst, DeciBio. Read More

#Exclusive Content #Trends & Analysis

DDW Antibodies eBook
#Antibodies #Antibody drug conjugate (ADC) #Antibody-based therapeutics #Drug development #Drug discovery

Antibody discovery: Breakthroughs accelerating therapeutic antibodies

This 24-page eBook sponsored by Carterra examines the market for therapeutic antibodies and the breakthroughs driving drug discovery in this sector. Download this exclusive eBook to learn more about: The market for therapeutic antibodies Advancements and challenges in the sector Trends in the antibody-drug conjugate (ADC) market… Read More

#DDW eBooks #Intelligence

#Antibodies #Drug development #Drug discovery #Guide

DDW Therapeutic Antibody Guide

Download the exclusive Guide and read about: The future of therapeutic antibodies From the top: Shining the spotlight on an industry leader The major disease areas for therapeutic antibodies… Read More

#DDW eBooks #DDW Guides

Seed funding
#AI / data analytics / healthtech / informatics #Investment #Omics #Seed funding #SMi Systems #Start-ups

SMi discloses £6 million seed funding round

SMi Systems has disclosed a £6m ($7.6m) seed funding round to develop and prove the utility of its multi-omic platform for in vitro diagnosis and biomedical research. SMi hopes the technology will significantly accelerate the discovery of new therapeutics by biopharma companies and research institutions. Read More

#News #Start-up Zone

#iPSC #Poster #Stem cells

Accelerated production of functional microglia from reprogrammed hiPSCs

In this scientific Poster, just revealed at ISSCR 2023, you will discover: How precision reprogramming generates consistent, functional human microglia (ioMicroglia) from iPSCs in just 10 days Independent validation that ioMicroglia undergo phagocytosis of both E. coli particles and amyloid beta particles Independent validation that ioMicroglia show… Read More

#Resources